ENTRADA THERAPEUTICS, INC. TRDA 深 沪
已收盘 11-07 16:00:00 美东时间
6.91
-0.040
-0.58%
华盛通- 最 高7.02
- 今 开6.83
- 成交量 35.17万股
- 最 低 6.35
- 昨 收 6.95
- 总市值 2.63亿
- 52周最高 21.79
- 市盈率 静 4.11
- 换手率 0.92%
- 52周最低 4.93
- 委 比 10.70%
- 总股本 3803.71万
- 历史最高 36.85
- 量 比 1.33
- 振 幅 9.64%
- 历史最低 4.93
- 每 手 1
- 风险率 4.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entrada Therapeutics Q3 EPS $(1.06) Misses $(0.95) Estimate, Sales $1.614M Miss $13.702M Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.95) by 11.58 percent. This is a 202.86 percent decrease over losses of $(0.35) per
11-06 20:12
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics announced its participation in two upcoming investor conferences. CEO Dipal Doshi will present at the Jefferies Global Healthcare Conference in London on November 18 and will join a fireside chat at the Evercore Healthcare Conference in Miami on December 3. Live webcasts and 90-day replays will be available on the company's website. Entrada, a clinical-stage biopharmaceutical company, develops novel intracellular therapies fo...
10-28 11:00
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Entrada Therapeutics announced the recipients of its 2025 DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy). These grants support programs advancing equity, accessibility, and inclusion for individuals with Duchenne muscular dystrophy in the U.S., EU, and U.K. Jett Foundation's Camp Promise provides year-round support for underserved individuals aged 18 and older, while Parent Project aps deliver...
09-05 11:00
Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.85) by 22.64 percent. This is a 167.1 percent decrease over earnings of $1.55 per share
08-06 19:34
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
Entrada Therapeutics Appoints New Board Member
An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On ...
06-03 19:28
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Entrada Therapeutics has appointed Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings extensive experience in global drug development, which will support Entrada's clinical progress, particularly in its Duchenne muscular dystrophy programs.
06-03 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 23,820 RSUs to six new non-executive employees under its 2025 Inducement Equity Plan. The RSUs vest with 25% after one year and 6.25% quarterly thereafter, contingent on continued employment. The company focuses on developing intracellular therapeutics for neuromuscular and ocular diseases.
06-02 20:30
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics has received EU authorization to initiate the ELEVATE-45-201 Phase 1/2 clinical trial for ENTR-601-45, targeting Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping. The global study will assess safety, tolerability, and efficacy, with plans to begin in Q3 2025.EN
05-28 11:00
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
